Odisha’s First Vaccine Manufacturing Plant ‘Sapigen Biologix’ To Start Production By May 2024

Bhubaneswar: Commercial production at the Sapigen Biologix vaccine plant in Odisha, the first such facility in the state, will commence by May this year, officials said on Sunday.

The plant at the Biotech Park in Andharua near here will have a capacity to produce 2.4 crore doses of different vaccines per day, they said.

At full capacity, this facility will be the biggest vaccine-producing plant in the country, the Chief Minister’s Office (CMO) said in a statement.

It is expected to produce over 15 vaccines for various diseases, including cholera and malaria.

The Rs 1,500-crore vaccine plant will create direct employment for 1,500 people, with most of them being local recruits, the CMO said.

The variety of vaccines produced in Bhubaneswar will be supplied to many parts of the world, it added.

V K Pandian, the chairman of ‘5T’ technology-led transformative initiatives on Sunday visited the sub-units and interacted with the management and employees. He urged all government agencies to assist in the commissioning of the plant within the next three months.

Related Posts

PGIMS recalls drug amid probe into deaths

The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

NPPA list brings little relief: No price cut for 25% cancer drugs

Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

PGIMS recalls drug amid probe into deaths

PGIMS recalls drug amid probe into deaths

NPPA list brings little relief: No price cut for 25% cancer drugs

NPPA list brings little relief: No price cut for 25% cancer drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

For Aakash Healthcare, Community People are Apples of its Eyes

For Aakash Healthcare, Community People are Apples of its Eyes